Hypoglycemia Clinical Trial
Official title:
A Retrospective Analysis of the Effects of a Hypoglycemia Protocol With Glucose Gel on NICU Admission
| NCT number | NCT04085978 |
| Other study ID # | 501938027 |
| Secondary ID | |
| Status | Terminated |
| Phase | |
| First received | |
| Last updated | |
| Start date | May 4, 2020 |
| Est. completion date | October 12, 2020 |
| Verified date | October 2020 |
| Source | Mednax Center for Research, Education, Quality and Safety |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Evaluate if the implementation of a hypoglycemia protocol with glucose gel has reduced the NICU admission rate of neonates with low-acuity neonatal hypoglycemia.
| Status | Terminated |
| Enrollment | 400 |
| Est. completion date | October 12, 2020 |
| Est. primary completion date | October 12, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 34 Weeks and older |
| Eligibility |
Inclusion Criteria: - All neonates born at Banner University Hospital during January 01, 2014 - November 30, 2016 and January 01, 2018 - November 30 2018 who qualify for hypoglycemia protocol. Exclusion Criteria: - Neonates <34 weeks gestational age or with birth weight less than 2000 grams. - Infants with serious congenital malformation - Infants with a terminal disorder. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Banner University Medical Center Phoenix | Phoenix | Arizona |
| Lead Sponsor | Collaborator |
|---|---|
| Mednax Center for Research, Education, Quality and Safety | Banner University Medical Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Mean NICU length of stay rounded to the day | Mean NICU length of stay rounded to the day | 30 days | |
| Primary | Mean maximum glucose infusion rate | Mean maximum glucose infusion rate | 30 days | |
| Secondary | Assess for complications | - Number of neonates identified to have any type of infection | 30 days | |
| Secondary | Assess for weight loss | - Maximum weight loss as percent below birth weight during NICU admission | 30 days | |
| Secondary | Evaluate for persistent symptomatic or asymptomatic hypoglycemia | Number of neonates with symptomatic hypoglycemia Number of neonates with asymptomatic hypoglycemia |
30 days | |
| Secondary | Number of neonates who received formula | Time to gain back to birthweight (if occurred while in-house), rounded to day of life | 30 days | |
| Secondary | Number of neonates with any breastfeeding during hospitalization | Time to gain back to birthweight (if occurred while in-house), rounded to day of life | 30 days | |
| Secondary | Number of neonates with breastfeeding at time of discharge | Time to gain back to birthweight (if occurred while in-house), rounded to day of life | 30 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
| Completed |
NCT03667053 -
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
|
Phase 3 | |
| Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
| Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
| Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A | |
| Not yet recruiting |
NCT05990933 -
Role of Adrenaline in in the Inflammatory Response in Diabetes
|
N/A | |
| Withdrawn |
NCT03736083 -
Introducing CGM at Type 1 Diabetes Diagnosis
|
N/A | |
| Completed |
NCT02966275 -
Post Bariatric Closed Loop Glucagon Trial
|
N/A | |
| Not yet recruiting |
NCT02909881 -
Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes
|
N/A | |
| Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
| Completed |
NCT02213003 -
Allogeneic Islet Cells Transplanted Onto the Omentum
|
Phase 1/Phase 2 | |
| Completed |
NCT01147276 -
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
|
Phase 4 | |
| Completed |
NCT01176656 -
Hypoglycemia: Physician and Patient Perspectives
|
N/A | |
| Completed |
NCT00998374 -
Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
|
N/A | |
| Terminated |
NCT01225159 -
Tight Glycaemic Control During Cardiac Surgery
|
N/A | |
| Completed |
NCT00373854 -
Study of How Low Blood Sugar Affects the Way Blood Vessels Work
|
N/A | |
| Completed |
NCT00285233 -
Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05916131 -
Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.
|
N/A | |
| Terminated |
NCT04026750 -
Insulin Tolerance Test Study in Patients With Type 1 Diabetes
|
Phase 1 | |
| Completed |
NCT05133765 -
The SMART B Exercise Study :''The SMART Study''
|
N/A |